

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**


IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESAL PRICE LITIGATION)	MDL NO. 1456
)	Civil Action No. 01-12257-PBS
)	Subcategory No.: 03-10643-PBS
)	(Doc. No. 8068 in Case No. 01-12257)
THIS DOCUMENT RELATES TO:)	
)	Judge Patti B. Saris
<i>The City of New York, et al. v. Abbott Laboratories, Inc., et al.</i>)	

**~~PROPOSED~~ ORDER OF DISMISSAL
AS TO CLAIMS AGAINST MYLAN**

Pursuant to Rule 41(a) of the Federal Rules of Civil Procedure, the plaintiffs the Consolidated New York Counties (the "Plaintiffs"), and defendants Mylan Inc. (formerly known as Mylan Laboratories Inc.), Mylan Pharmaceuticals Inc. and Mylan Institutional Inc. (formerly known as UDL Laboratories, Inc.) (collectively, "Mylan") have filed a Stipulation of Dismissal as to the claims asserted by Plaintiffs against Mylan in the consolidated action entitled *In re Pharmaceutical Industry Average Wholesale Price Litigation: The City of New York, et al. v. Abbott Laboratories, Inc., et al.* (MDL No. 01-CV-12257-PBS, Subcategory No. 03-10643) (the "Litigation"). Upon due consideration of the Stipulation and the papers on file in this action,

IT IS HEREBY ORDERED that, consistent with the terms of the Settlement Agreement and Release, effective January 25, 2012 (the "Settlement Agreement") all claims asserted against Mylan are dismissed with prejudice, each party shall bear its own costs except as otherwise provided for in the Settlement Agreement, and all rights of appeal shall be waived.

Entered this 13 day of February, 2012.


 Patti B. Saris, J.
 United States District Court